Biological bioadhesive compositions and methods of preparation and use
The present invention relates generally to the preparation and use of biological tissue adhesives which rely on combining fibrinogen and thrombin. More particularly, the present invention relates to a method of preparing a fibrin sealant whereby said sealant is formed by reconstituting the fibrinogen or the thrombin component in the presence of biological and/or non-biological agents such as drugs, chemicals, and proteins. Preferably, these agents are introduced in solution, such as for example, a corticosteroid-containing solution like a betamethasone solution containing betamethasone acetate or betamethasone sodium phosphate; a triamicinolone solution; or a methylprednisolone solution. These solutions may be substituted for, or provided as a complement to, other solutions that are typically used in the preparation of fibrin sealants such as, for example, calcium chloride. The invention further relates to a novel method of using the improved fibrin sealant whereby the sealant and accompanying agent(s) are delivered directly to a critical site within the body and sealed in place due to the bio-static quality of the sealant. This provides therapeutic value to patients through prolonged presence, and optionally time-released delivery, of the specific agent(s) at the critical site.
1. A system for delivering a biological tissue adhesive, comprising:
a fibrinogen component;
a thrombin component, and
a corticosteroid-containing solution, wherein the corticosteroid is betamethasone.
2. The system of claim 1 , further comprising a calcium chloride solution.
3. The system of claim 1 , wherein the thrombin and corticosteroid-containing solution are in a single vial.
4. The system of claim 1 , wherein the thrombin is in one vial and the corticosteroid-containing solution is in a second vial.
5. The system of claim 1 , further comprising a Y connector.
6. The system of claim 1 , further comprising a dual-syringe.
7. The system of claim 1 , further comprising at least one curved spinal needle.
8. The system of claim 1 , further comprising a contrast agent component.
9. The system of claim 1 , wherein the corticosteroid is betamethasone acetate.
10. The system of claim 1 , wherein the corticosteroid is betamethasone sodium phosphate.
11. The system of claim 1 , wherein the fibrinogen component is in a freeze-dried state.
12. The system of claim 1 , wherein the thrombin is in the freeze-dried state.
13. The system of claim 1 , further comprising an anti-caking component.
14. The system of claim 1 , further comprising a polysorbate anti-caking component.
15. The system of claim 1 , further comprising at least one additional component selected from the group consisting of an antibiotic, an antiproliferative/cytotoxic drug, an antiviral, a cytokine, a colony stimulating factor, erythropoietin, an antifungal, an antiparasitic agent, an anti-inflammatory agent, a steroid, an anesthetic, an analgesic, an oncology agent, a hormone, a glycoprotein, fibronectin, a peptide, a protein, a carbohydrate, a protoglycan, an antiangiogenin, an antigen, an oligonucleotide, a BMP, a DBM, an antibody, a gene therapy reagent, a cell, a stem cell, a cell growth factor, an oxygen-containing component, an enzyme, a nutrient, or a growth factor.
16. The method of claim 1 , wherein the fibrinogen is removed from the human body of claim 1 .
17. The method of claim 1 , wherein the fibrinogen is derived from frozen fibrinogen.
18. A system for delivering a biological tissue adhesive, comprising:
a freeze-dried fibrinogen component;
a freeze-dried thrombin component, and
a corticosteroid-containing solution, wherein the corticosteroid is betamethasone.
19. The system of claim 18 , further comprising a calcium chloride solution.
20. The system of claim 18 , wherein the thrombin is in one vial and the corticosteroid-containing solution is in a second vial.
21. The system of claim 18 , further comprising a Y connector.
22. The system of claim 18 , further comprising a dual-syringe.
23. The system of claim 18 , further comprising at least one curved spinal needle.
24. The system of claim 18 , further comprising a contrast agent component.
25. The system of claim 18 , wherein the corticosteroid is betamethasone acetate.
26. The system of claim 18 , wherein the corticosteroid is betamethasone sodium phosphate.
27. The system of claim 18 , further comprising an anti-caking component.
28. The system of claim 18 , further comprising a polysorbate anti-caking component.
29. The system of claim 18 , further comprising at least one additional component selected from the group consisting of an antibiotic, an antiproliferative/cytotoxic drug, an antiviral, a cytokine, a colony stimulating factor, erythropoietin, an antifungal, an antiparasitic agent, an anti-inflammatory agent, a steroid, an anesthetic, an analgesic, an oncology agent, a hormone, a glycoprotein, fibronectin, a peptide, a protein, a carbohydrate, a protoglycan, an antiangiogenin, an antigen, an oligonucleotide, a BMP, a DBM, an antibody, a gene therapy reagent, a cell, a stem cell, a cell growth factor, an oxygen-containing component, an enzyme, a nutrient, or a growth factor.
30. A system for delivering a biological tissue adhesive, comprising:
a freeze-dried fibrinogen component;
a freeze-dried thrombin component;
a betamethasone-containing solution;
a spinal needle; and
a dual syringe.
31. The system of claim 30 , further comprising a calcium chloride solution.
32. The system of claim 30 , wherein the thrombin is in one vial and the betamethasone-containing solution is in a second vial.
33. The system of claim 30 , wherein the spinal needle is curved.
34. The system of claim 30 , further comprising a contrast agent component.
35. The system of claim 30 , further comprising an anti-caking component.
36. The system of claim 30 , further comprising a polysorbate anti-caking component.
37. The system of claim 30 , further comprising at least one additional component selected from the group consisting of an antibiotic, an antiproliferative/cytotoxic drug, an antiviral, a cytokine, a colony stimulating factor, erythropoietin, an antifungal, an antiparasitic agent, an anti-inflammatory agent, a steroid, an anesthetic, an analgesic, an oncology agent, a hormone, a glycoprotein, fibronectin, a peptide, a protein, a carbohydrate, a protoglycan, an antiangiogenin, an antigen, an oligonucleotide, a BMP, a DBM, an antibody, a gene therapy reagent, a cell, a stem cell, a cell growth factor, an oxygen-containing component, an enzyme, a nutrient, or a growth factor.
38. The system of claim 30 , wherein the betamethasone is betamethasone acetate.
39. The system of claim 30 , wherein the betamethasone is betamethasone sodium phosphate.